Drugs watchdog condemns Roche for high price of breast cancer therapy
February 19, 2016 by Webmaster at ecancer.org in
The pharmaceuticals giant Roche has been criticised in unprecedented terms by the government’s drugs watchdog for refusing to significantly lower the price of a breast cancer drug whose £90,000-per-patient cost is well over the NHS’s limit.
The National Institute for Health and Care Excellence (Nice), says it cannot recommend the drug, Kadcyla, which promises extra months of life for women with advanced breast cancer, because of Roche’s inflexibility.
